Sandbox:Preeti: Difference between revisions
Jump to navigation
Jump to search
Preeti Singh (talk | contribs) No edit summary |
Preeti Singh (talk | contribs) No edit summary |
||
Line 7: | Line 7: | ||
! colspan="2" rowspan="4" align="center" style="background:#4479BA; color: #FFFFFF;" + |Disease | ! colspan="2" rowspan="4" align="center" style="background:#4479BA; color: #FFFFFF;" + |Disease | ||
! rowspan="4" align="center" style="background:#4479BA; color: #FFFFFF;" + |Etiology | ! rowspan="4" align="center" style="background:#4479BA; color: #FFFFFF;" + |Etiology | ||
! colspan=" | ! colspan="7" rowspan="2" |Clinical manifestations | ||
! colspan=" | ! colspan="5" align="center" style="background:#4479BA; color: #FFFFFF;" + |Paraclinical findings | ||
! rowspan="4" align="center" style="background:#4479BA; color: #FFFFFF;" + |Gold standard | ! rowspan="4" align="center" style="background:#4479BA; color: #FFFFFF;" + |Gold standard | ||
! rowspan="4" align="center" style="background:#4479BA; color: #FFFFFF;" + |Associated findings | ! rowspan="4" align="center" style="background:#4479BA; color: #FFFFFF;" + |Associated findings | ||
|- | |- | ||
! colspan=" | ! colspan="5" align="center" style="background:#4479BA; color: #FFFFFF;" + |Lab findings | ||
|- | |- | ||
! colspan="4" align="center" style="background:#4479BA; color: #FFFFFF;" + |Symptoms | ! colspan="4" align="center" style="background:#4479BA; color: #FFFFFF;" + |Symptoms | ||
! colspan=" | ! colspan="3" |Signs | ||
! colspan="3" align="center" style="background:#4479BA; color: #FFFFFF;" + |CBC | ! colspan="3" align="center" style="background:#4479BA; color: #FFFFFF;" + |CBC | ||
! rowspan="2" align="center" style="background:#4479BA; color: #FFFFFF;" + |Immunochemistry | ! rowspan="2" align="center" style="background:#4479BA; color: #FFFFFF;" + |Immunochemistry | ||
! rowspan="2" align="center" style="background:#4479BA; color: #FFFFFF;" + |Histopathology | ! rowspan="2" align="center" style="background:#4479BA; color: #FFFFFF;" + |Histopathology | ||
|- | |- | ||
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Constitutional symptoms | ! align="center" style="background:#4479BA; color: #FFFFFF;" + |Constitutional symptoms | ||
Line 29: | Line 24: | ||
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Abdominal pain | ! align="center" style="background:#4479BA; color: #FFFFFF;" + |Abdominal pain | ||
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Diarrhea | ! align="center" style="background:#4479BA; color: #FFFFFF;" + |Diarrhea | ||
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Mass | ! align="center" style="background:#4479BA; color: #FFFFFF;" + |Mass | ||
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Hepatosplenomegaly | ! align="center" style="background:#4479BA; color: #FFFFFF;" + |Hepatosplenomegaly | ||
Line 37: | Line 31: | ||
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Plt | ! align="center" style="background:#4479BA; color: #FFFFFF;" + |Plt | ||
|- | |- | ||
! colspan=" | ! colspan="18" align="left" style="background:#4479BA; color: #FFFFFF;" + |HL | ||
|- | |- | ||
! align="center" style="background:#4479BA; color: #FFFFFF;" + | | ! align="center" style="background:#4479BA; color: #FFFFFF;" + | | ||
! colspan="2" align="center" style="background:#DCDCDC;" + |Hodgkin's Lymphoma | ! colspan="2" align="center" style="background:#DCDCDC;" + |Hodgkin's Lymphoma | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 63: | Line 51: | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
|- | |- | ||
! colspan=" | ! colspan="18" align="left" style="background:#4479BA; color: #FFFFFF;" + |NHL | ||
|- | |- | ||
! rowspan="12" align="center" style="background:#4479BA; color: #FFFFFF;" + |B Cell Lymphoma | ! rowspan="12" align="center" style="background:#4479BA; color: #FFFFFF;" + |B Cell Lymphoma | ||
Line 71: | Line 59: | ||
*Unknown | *Unknown | ||
*Inherited mutations of PAX5, ETV6, and TP53 | *Inherited mutations of PAX5, ETV6, and TP53 | ||
| align="center" style="background:#F5F5F5;" + | + | | align="center" style="background:#F5F5F5;" + | + | ||
| align="center" style="background:#F5F5F5;" + |– | | align="center" style="background:#F5F5F5;" + |– | ||
| align="center" style="background:#F5F5F5;" + |– | | align="center" style="background:#F5F5F5;" + |– | ||
| align="center" style="background:#F5F5F5;" + |– | | align="center" style="background:#F5F5F5;" + |– | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + |± | | align="center" style="background:#F5F5F5;" + |± | ||
Line 95: | Line 72: | ||
| align="center" style="background:#F5F5F5;" + |↓ | | align="center" style="background:#F5F5F5;" + |↓ | ||
| align="center" style="background:#F5F5F5;" + |Nl to ↓ | | align="center" style="background:#F5F5F5;" + |Nl to ↓ | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 109: | Line 83: | ||
* Reciprocal translocation t(14;18) | * Reciprocal translocation t(14;18) | ||
* Overexpression of ''BCL2'' | * Overexpression of ''BCL2'' | ||
| align="left" style="background:#F5F5F5;" + |Only in 20% of patients: | | align="left" style="background:#F5F5F5;" + |Only in 20% of patients: | ||
*[[Fever]] | *[[Fever]] | ||
Line 123: | Line 90: | ||
| align="center" style="background:#F5F5F5;" + | + | | align="center" style="background:#F5F5F5;" + | + | ||
| align="center" style="background:#F5F5F5;" + |± | | align="center" style="background:#F5F5F5;" + |± | ||
| align="left" style="background:#F5F5F5;" + | | | align="left" style="background:#F5F5F5;" + | | ||
* Painless peripheral adenopathy in the cervical, axillary, inguinal, and/or femoral regions | * Painless peripheral adenopathy in the cervical, axillary, inguinal, and/or femoral regions | ||
Line 137: | Line 103: | ||
| align="center" style="background:#F5F5F5;" + |↓ | | align="center" style="background:#F5F5F5;" + |↓ | ||
| align="center" style="background:#F5F5F5;" + |Nl to ↓ | | align="center" style="background:#F5F5F5;" + |Nl to ↓ | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
* CD21 | * CD21 | ||
Line 145: | Line 108: | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
* Nodular growth pattern | * Nodular growth pattern | ||
| align="center" style="background:#F5F5F5;" + |Lymph node biopsy | | align="center" style="background:#F5F5F5;" + |Lymph node biopsy | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 157: | Line 118: | ||
* [[CD5 (protein)|CD5]] positive antigen in pregerminal center of B-cell | * [[CD5 (protein)|CD5]] positive antigen in pregerminal center of B-cell | ||
* [[Chromosomal translocation]] at '''t(11:14)''' | * [[Chromosomal translocation]] at '''t(11:14)''' | ||
| align="left" style="background:#F5F5F5;" + | | | align="left" style="background:#F5F5F5;" + | | ||
* Fatigue | * Fatigue | ||
Line 165: | Line 124: | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + |Abdominal distention | | align="center" style="background:#F5F5F5;" + |Abdominal distention | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 179: | Line 137: | ||
| align="center" style="background:#F5F5F5;" + |↓ | | align="center" style="background:#F5F5F5;" + |↓ | ||
| align="center" style="background:#F5F5F5;" + |Nl to ↓ | | align="center" style="background:#F5F5F5;" + |Nl to ↓ | ||
| align="left" style="background:#F5F5F5;" + | | | align="left" style="background:#F5F5F5;" + | | ||
* CD5<sup>+</sup> | * CD5<sup>+</sup> | ||
Line 188: | Line 144: | ||
* Germinal centers filled by small-to-medium atypical lymphocytes | * Germinal centers filled by small-to-medium atypical lymphocytes | ||
* Nodular appearance | * Nodular appearance | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 200: | Line 154: | ||
* Mutation of ''BCL6'', ''MYC'', ''[[PAX5]]'', ''[[PIM1]]'', ''[[RhoH]]'' /''TTFn'', ''[[TP53]]'' genes | * Mutation of ''BCL6'', ''MYC'', ''[[PAX5]]'', ''[[PIM1]]'', ''[[RhoH]]'' /''TTFn'', ''[[TP53]]'' genes | ||
* Translocations involving ''c-MYC'', ''BCL6'', and ''IgH'' gene. | * Translocations involving ''c-MYC'', ''BCL6'', and ''IgH'' gene. | ||
| align="left" style="background:#F5F5F5;" + | | | align="left" style="background:#F5F5F5;" + | | ||
* Fever | * Fever | ||
* Night sweats | * Night sweats | ||
* weight loss | * weight loss | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 217: | Line 168: | ||
| align="center" style="background:#F5F5F5;" + |↓ | | align="center" style="background:#F5F5F5;" + |↓ | ||
| align="center" style="background:#F5F5F5;" + |Nl to ↓ | | align="center" style="background:#F5F5F5;" + |Nl to ↓ | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="left" style="background:#F5F5F5;" + | | | align="left" style="background:#F5F5F5;" + | | ||
Line 230: | Line 178: | ||
'''Anaplastic''' | '''Anaplastic''' | ||
*Very large cells with a round, oval, or polygonal shape that may resemble Reed-Sternberg cells | *Very large cells with a round, oval, or polygonal shape that may resemble Reed-Sternberg cells | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 237: | Line 183: | ||
! colspan="2" align="center" style="background:#4479BA; color: #FFFFFF;" + |Disease | ! colspan="2" align="center" style="background:#4479BA; color: #FFFFFF;" + |Disease | ||
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Etiology | ! align="center" style="background:#4479BA; color: #FFFFFF;" + |Etiology | ||
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Constitutional symptoms | ! align="center" style="background:#4479BA; color: #FFFFFF;" + |Constitutional symptoms | ||
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Rash | ! align="center" style="background:#4479BA; color: #FFFFFF;" + |Rash | ||
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Abdominal pain | ! align="center" style="background:#4479BA; color: #FFFFFF;" + |Abdominal pain | ||
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Diarrhea | ! align="center" style="background:#4479BA; color: #FFFFFF;" + |Diarrhea | ||
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Mass | ! align="center" style="background:#4479BA; color: #FFFFFF;" + |Mass | ||
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Hepatosplenomegaly | ! align="center" style="background:#4479BA; color: #FFFFFF;" + |Hepatosplenomegaly | ||
Line 250: | Line 193: | ||
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Hb | ! align="center" style="background:#4479BA; color: #FFFFFF;" + |Hb | ||
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Plt | ! align="center" style="background:#4479BA; color: #FFFFFF;" + |Plt | ||
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Immunochemistry | ! align="center" style="background:#4479BA; color: #FFFFFF;" + |Immunochemistry | ||
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Histopathology | ! align="center" style="background:#4479BA; color: #FFFFFF;" + |Histopathology | ||
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Gold standard | ! align="center" style="background:#4479BA; color: #FFFFFF;" + |Gold standard | ||
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Associated findings | ! align="center" style="background:#4479BA; color: #FFFFFF;" + |Associated findings | ||
Line 265: | Line 205: | ||
** t(2;8) | ** t(2;8) | ||
** t(8;22) | ** t(8;22) | ||
| align="left" style="background:#F5F5F5;" + | | | align="left" style="background:#F5F5F5;" + | | ||
* [[Fever]] | * [[Fever]] | ||
* [[Night sweats]] | * [[Night sweats]] | ||
* Unexplained [[weight loss]] | * Unexplained [[weight loss]] | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 284: | Line 221: | ||
* [[Ascites]] | * [[Ascites]] | ||
* [[Proptosis]] | * [[Proptosis]] | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 300: | Line 235: | ||
* [[basophilic]] cytoplasm | * [[basophilic]] cytoplasm | ||
* "Starry-sky pattern" | * "Starry-sky pattern" | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 307: | Line 241: | ||
| align="left" style="background:#F5F5F5;" + | | | align="left" style="background:#F5F5F5;" + | | ||
* Mature B-cell Lymphoma | * Mature B-cell Lymphoma | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 332: | Line 260: | ||
| align="left" style="background:#F5F5F5;" + | | | align="left" style="background:#F5F5F5;" + | | ||
* Mature B-cell Lymphoma | * Mature B-cell Lymphoma | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 359: | Line 281: | ||
** Deletion 7q21-32 | ** Deletion 7q21-32 | ||
** Translocations of the CDK6 gene located on 7q21 | ** Translocations of the CDK6 gene located on 7q21 | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 382: | Line 299: | ||
* Epithelial histocytes | * Epithelial histocytes | ||
* Plasmacytic differentiation of neoplastic cells | * Plasmacytic differentiation of neoplastic cells | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 390: | Line 306: | ||
* Mature B-cell Lymphoma | * Mature B-cell Lymphoma | ||
* Stimulation of antigen receptor by autoantigen and co-stimulatory molecule CD40 | * Stimulation of antigen receptor by autoantigen and co-stimulatory molecule CD40 | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | + | | align="center" style="background:#F5F5F5;" + | + | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 405: | Line 318: | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="left" style="background:#F5F5F5;" + | | | align="left" style="background:#F5F5F5;" + | | ||
* Follicular cells in reactive zone | * Follicular cells in reactive zone | ||
* Centrocyte like cells in marginal zone lymphoma | * Centrocyte like cells in marginal zone lymphoma | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 424: | Line 332: | ||
| align="left" style="background:#F5F5F5;" + | | | align="left" style="background:#F5F5F5;" + | | ||
* Mature B-cell Lymphoma | * Mature B-cell Lymphoma | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 451: | Line 353: | ||
** The ''MEK-ERK'' cascade | ** The ''MEK-ERK'' cascade | ||
** The ''Phosphatidylinositol 3 kinase (PI3K)-AKT'' cascade | ** The ''Phosphatidylinositol 3 kinase (PI3K)-AKT'' cascade | ||
| align="left" style="background:#F5F5F5;" + | | | align="left" style="background:#F5F5F5;" + | | ||
* [[Fever]] | * [[Fever]] | ||
Line 462: | Line 362: | ||
* Recurrent [[Infection|infections]] | * Recurrent [[Infection|infections]] | ||
* Early satiety | * Early satiety | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 478: | Line 377: | ||
** Decreased [[platelets]] count | ** Decreased [[platelets]] count | ||
** | ** | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 496: | Line 393: | ||
* Central round [[nucleus]] | * Central round [[nucleus]] | ||
* Peri-nuclear clearing ("water-clear rim" appearance) | * Peri-nuclear clearing ("water-clear rim" appearance) | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 504: | Line 400: | ||
| align="left" style="background:#F5F5F5;" + | | | align="left" style="background:#F5F5F5;" + | | ||
* Precursor T-cell Lymphomas | * Precursor T-cell Lymphomas | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 528: | Line 418: | ||
| align="left" style="background:#F5F5F5;" + | | | align="left" style="background:#F5F5F5;" + | | ||
* Mature T-cell Lymphoma | * Mature T-cell Lymphoma | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 552: | Line 436: | ||
| align="left" style="background:#F5F5F5;" + | | | align="left" style="background:#F5F5F5;" + | | ||
* Mature T-cell Lymphoma | * Mature T-cell Lymphoma | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 579: | Line 457: | ||
* The [[tumor]] [[Cell (biology)|cells]] originate from [[memory T cells]] or [[skin]] homing [[CD4+ T cells]] expressing [[cutaneous]] [[lymphocyte]] [[antigen]] (CLA) an<nowiki/>d [[chemokine]] [[receptors]] [[CCR4]]<nowiki/>and CCR7. | * The [[tumor]] [[Cell (biology)|cells]] originate from [[memory T cells]] or [[skin]] homing [[CD4+ T cells]] expressing [[cutaneous]] [[lymphocyte]] [[antigen]] (CLA) an<nowiki/>d [[chemokine]] [[receptors]] [[CCR4]]<nowiki/>and CCR7. | ||
* It is understood that cutaneous t cell lymphoma (maycosis fungoides, Sezary sydrome ) is the result of malignant T cell that derived from a mature CD41 CD45RO1 memory T cells. | * It is understood that cutaneous t cell lymphoma (maycosis fungoides, Sezary sydrome ) is the result of malignant T cell that derived from a mature CD41 CD45RO1 memory T cells. | ||
| align="left" style="background:#F5F5F5;" + | | | align="left" style="background:#F5F5F5;" + | | ||
* [[Epidermis (skin)|Epidermal]] [[atrophy]] or poikiloderma | * [[Epidermis (skin)|Epidermal]] [[atrophy]] or poikiloderma | ||
Line 592: | Line 468: | ||
* [[Anemia]] | * [[Anemia]] | ||
* May progress to [[Sezary syndrome]] (Skin involvement plus hematogenous dissemination) | * May progress to [[Sezary syndrome]] (Skin involvement plus hematogenous dissemination) | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 598: | Line 473: | ||
| align="left" style="background:#F5F5F5;" + | | | align="left" style="background:#F5F5F5;" + | | ||
* Cutaneous manifestations | * Cutaneous manifestations | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 615: | Line 487: | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
* Mature T-cell Lymphoma | * Mature T-cell Lymphoma | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 639: | Line 505: | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
* Mature T-cell Lymphoma | * Mature T-cell Lymphoma | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 663: | Line 523: | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
* Mature T-cell Lymphoma | * Mature T-cell Lymphoma | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 687: | Line 541: | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
* Mature T-cell Lymphoma | * Mature T-cell Lymphoma | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 711: | Line 559: | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
* Mature T-cell Lymphoma | * Mature T-cell Lymphoma | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 735: | Line 577: | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
* Mature T-cell Lymphoma | * Mature T-cell Lymphoma | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | |
Revision as of 16:19, 17 January 2019
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Preeti Singh, M.B.B.S.[2]
Category | Disease | Etiology | Clinical manifestations | Paraclinical findings | Gold standard | Associated findings | |||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Lab findings | |||||||||||||||||
Symptoms | Signs | CBC | Immunochemistry | Histopathology | |||||||||||||
Constitutional symptoms | Rash | Abdominal pain | Diarrhea | Mass | Hepatosplenomegaly | Other | WBC | Hb | Plt | ||||||||
HL | |||||||||||||||||
Hodgkin's Lymphoma | |||||||||||||||||
NHL | |||||||||||||||||
B Cell Lymphoma | B-lymphoblastic leukemia/lymphoma |
|
+ | – | – | – | ± |
|
↓ | ↓ | Nl to ↓ |
| |||||
Follicular lymphoma |
|
Only in 20% of patients: | + | + | ± |
|
+ | ↓ | ↓ | Nl to ↓ |
|
|
Lymph node biopsy |
| |||
Mantle cell lymphoma |
|
|
Abdominal distention |
|
+ |
|
|
↓ | Nl to ↓ |
|
|
||||||
Diffuse large B cell lymphoma |
|
|
|
↓ | ↓ | Nl to ↓ |
Centroblastic
Immunoblastic
Anaplastic
|
||||||||||
Disease | Etiology | Constitutional symptoms | Rash | Abdominal pain | Diarrhea | Mass | Hepatosplenomegaly | Other | WBC | Hb | Plt | Immunochemistry | Histopathology | Gold standard | Associated findings | ||
Burkitt lymphoma |
|
|
|
|
|||||||||||||
B cell chronic lymphocytic leukemia/small lymphocytic lymphoma |
|
||||||||||||||||
Marginal zone lymphoma | Extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue (MALT) type |
|
|||||||||||||||
Splenic marginal zone lymphoma |
|
|
|||||||||||||||
Nodal marginal zone B-cell lymphoma |
|
+ |
|
|
| ||||||||||||
Lymphoplasmacytic lymphoma (Waldenstrom’s macroglobulinemia) |
|
||||||||||||||||
Hairy cell leukemia |
|
|
|
||||||||||||||
T cell lymphoma | Precursor T-cell lymphoblastic leukemia/lymphoma |
|
|||||||||||||||
Adult T cell leukemia/lymphoma |
|
||||||||||||||||
Anaplastic large cell lymphoma |
|
||||||||||||||||
Cutaneous T-cell lymphoma | Mycosis fungoides / Sézary syndrome |
|
|
|
|||||||||||||
Peripheral T-cell lymphoma | Subcutaneous panniculitis-like T-cell lymphoma |
|
|||||||||||||||
Hepatosplenic gamma-delta T-cell lymphoma |
|
||||||||||||||||
Enteropathy-type intestinal T-cell lymphoma |
|
||||||||||||||||
Extranodal T-cell lymphoma, nasal type |
|
||||||||||||||||
Angioimmunoblastic T-cell lymphoma |
|
||||||||||||||||
Peripheral T-cell lymphoma, unspecified |
|